Journal of Yeungnam Medical Science

Review article

Ocular adnexal mucosa-associated lymphoid tissue lymphoma: a narrative review: Hyun Uk Chung, Jun Hyuk Son; J Yeungnam Med Sci. 2022;39(1):3-11. Published online September 15, 2021; DOI: https://doi.org/10.12701/yujm.2021.01263

5,585 View
160 Download
8 Web of Science
6 Crossref

Lymphoma is the most common primary tumor of the orbit, accounting for 55% of all orbital malignancies. When divided into histopathological subtypes, extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) comprises the largest proportion. Clinical manifestations are unspecific, but in patients with slow-growing painless orbital mass, or red conjunctival lesion suggestive of ‘salmon patch’, ocular adnexa lymphoma (OAL) should be suspected. Although the pathogenetic mechanism of ocular adnexal MALT lymphoma (OAML) is not yet fully understood, the relationship between OAML and Chlamydia psittaci has been hypothesized recently, similar to that between gastric MALT lymphoma and Helicobacter pylori. This suggests a new treatment option for OAML; bacterial eradication therapy with systemic antibiotics. Several other treatment methods for OAML have been introduced, but no treatment guidelines have been established yet. In this article, we summarize the current knowledge on the clinical features, pathogenesis, diagnostic methods, therapeutic strategies, and prognosis of OAML.

Citations

Citations to this article as recorded by

Unusual Pediatric Red Eye
Carson W. Ercanbrack, Jamal O. Azhari, David B. Warner, Maher Abulfaraj, Abdelrahman M. Elhusseiny
The Journal of Pediatrics.2024; 267: 113924. CrossRef
The Possible Role of Pathogens and Chronic Immune Stimulation in the Development of Diffuse Large B-Cell Lymphoma
Lajos Gergely, Miklos Udvardy, Arpad Illes
Biomedicines.2024; 12(3): 648. CrossRef
Radiomics analysis of T1WI and T2WI magnetic resonance images to differentiate between IgG4-related ophthalmic disease and orbital MALT lymphoma
Yuchao Shao, Yuqing Chen, Sainan Chen, Ruili Wei
BMC Ophthalmology.2023;[Epub] CrossRef
Etiopathogenesis of primary acquired nasolacrimal duct obstruction (PANDO)
Mohammad Javed Ali
Progress in Retinal and Eye Research.2023; 96: 101193. CrossRef
The Biology of Ocular Adnexal Marginal Zone Lymphomas
Patricia Johansson, Anja Eckstein, Ralf Küppers
Cancers.2022; 14(5): 1264. CrossRef
One Case of Conjunctival MALT Lymphoma and Literature Review
旭霞李
Advances in Clinical Medicine.2022; 12(08): 7586. CrossRef

Review Article

Clinical Update: Inflammatory Bowel Disease: Byung Ik Jang; Yeungnam Univ J Med. 2007;24(2 Suppl):S221-233. Published online December 31, 2007; DOI: https://doi.org/10.12701/yujm.2007.24.2S.S221

1,403 View
3 Download
1 Crossref

Abstract PDF

Inflammatory bowel disease(IBD) which is well known as Crohn’s disease and ulcerative colitis is a chronic disorder that repeats improvement and exacerbation. The possible causes of the disease are environmental factors, genetic factors and immune deficiency resulted from bacterial infection. Recently, IL-23 is proved to be a main cytokine which has a central role in Crohn’s disease. The diagnosis of IBD is made by clinical manifestation, serologic test, endoscopic finding and histologic finding. The mainstay of remission and maintenance therapy of ulcerative colitis is 5-aminosalicylate(5-ASA). Steroid can be used in severe or refractory case and nowadays, budesonide shows a good effect with minimal side effects. In cases of steroid dependent, we can use the immunomodulators such as azathioprine, cyclosporin and 6-thioguanine. The cytokine associated with inflammation of IBD has been emphasized and the treatment which targets the cytokine such as tumor necrosis factor is tried. Infliximab and adalimumab block tumor necrosis factors-a and they are proved the efficacy by many clinical trial. Leukocytapheresis(LCAP) is tried in ulcerative colitis since 1980 in Japan. When we treat IBD patients, we need to consider all the things such as safety, side effects and economy of the patients. We expect that the development of new biologic agent which is more cost effective and more effect with more convinience.

Citations

Citations to this article as recorded by

Inflammatory Bowel Disease and Cytokine
Eun Young Choi, Kwang Keun Cho, In Soon Choi
Journal of Life Science.2013; 23(3): 448. CrossRef

Review

Hirschsprung's Disease.: Nam Hyuk Lee; Yeungnam Univ J Med. 2007;24(1):11-23. Published online June 30, 2007; DOI: https://doi.org/10.12701/yujm.2007.24.1.11

1,593 View
4 Download

Abstract PDF: Hirschsprung's disease is one of the most common causes of intestinal obstruction in neonates and infants. The underlying pathology of this disease is the absence of the ganglion cells in both the myenteric (Auerbach's) plexus and the submucosal (Meissner's) plexus. Since Hirschsprung's report in 1886, there have been thousands of papers on Hirschsprung's disease but the cause of the absence of the ganglion cells has not been identified. Hirschsprung's disease can be successfully treated with the Swenson, the Duhamel, and the Soave operations even though the pathogenesis is unknown. With the recent progress of molecular biology and genetics, a more detailed approach to the pathogenesis of Hirschsprung's disease can be undertaken. In addition, there have been recent developments in the surgical approach. In this review, recent advances in surgery for Hirschsprung's disease are presented.

First
Prev
Page of 1
Next
Last

Search